Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 64M P/E - EPS this Y - Ern Qtrly Grth -
Income -25.65M Forward P/E -2.42 EPS next Y -12.00% 50D Avg Chg -3.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 1.67 EPS next 5Y - 52W High Chg -80.00%
Recommedations 2.00 Quick Ratio 3.61 Shares Outstanding 54.98M 52W Low Chg 67.00%
Insider Own 45.57% ROA -34.78% Shares Float 30.66M Beta -
Inst Own 6.29% ROE -78.85% Shares Shorted/Prior 871.11K/180.50K Price 1.26
Gross Margin - Profit Margin - Avg. Volume 42,709 Target Price 8.00
Oper. Margin - Earnings Date May 13 Volume 26,008 Change 0.80%
About Vivani Medical, Inc.

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Vivani Medical, Inc. News
03/26/24 Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results
03/26/24 Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
03/06/24 Vivani Medical Appoints Daniel Bradbury to its Board of Directors
03/01/24 Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
03/01/24 Individual investors invested in Vivani Medical, Inc. (NASDAQ:VANI) up 287% last week, insiders too were rewarded
02/28/24 EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows
02/28/24 Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
12/24/23 Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 1.2% More Shares
06:02 AM Is Vivani Medical (NASDAQ:VANI) In A Good Position To Invest In Growth?
11/14/23 Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
10/16/23 Vivani Medical to Present at BIO Investor Forum
09/13/23 Director Gregg Williams Acquires 13,997 Shares of Vivani Medical Inc (VANI)
09/10/23 Insider Buys Additional US$50k In Vivani Medical Stock
09/07/23 Vivani Medical to Present at the Boulder Peptide Symposium
09/05/23 Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
08/14/23 Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
07/11/23 Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
06/14/23 Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
05/15/23 Vivani Medical Reports First Quarter Financial Results and Provides Business Update
05/03/23 Insiders of Vivani Medical, Inc. (NASDAQ:VANI) received good value on their investment after their US$2.2m purchase jumped US$593k in value
VANI Chatroom

User Image Lotsofdollars Posted - 19 hours ago

$VANI really a piece of shit , weakest link.

User Image Kkai14 Posted - 1 day ago

$VANI when when when

User Image MarcoPolo1111 Posted - 2 days ago

$VANI go

User Image Pathonix Posted - 2 days ago

$VANI NanoPortal: A Revolutionary Advancement in Drug Delivery Investors who previously backed the failed ITCA 650 device from Intarcia Therapeutics, which at one point was valued at $5 billion, have likely realized their mistake. Intarcia Therapeutics had raised more than $1 billion in private funding for the ITCA 650 device, which was designed to release a steady flow of the active drug contained in Bristol Myers Squibb's shot Bydureon. The ITCA 650 device faced FDA approval challenges due to erratic drug delivery caused by its osmotic pump mechanism. Vivani's NanoPortal technology operates without any moving parts, a crucial difference that offers patients a potentially life-altering solution. The success of Vivani's animal studies has paved the way for eagerly awaited human trials, holding the promise of a groundbreaking FDA approval.

User Image Durand32 Posted - 2 days ago

$VANI This might be stuck for awhile. Looks like the next catalysts are the Cortigent IPO and getting the clinical hold on NPM 119 lifted but those might still be months away.

User Image RallyRaider Posted - 3 days ago

$VANI lets see how it plays out. can revisit that high quickly. on watch.. need to do some digging

User Image Pathonix Posted - 3 days ago

$VANI Just added more.... I have faith

User Image Rounderssss4 Posted - 3 days ago

$VANI come on reverse

User Image Aviator47 Posted - 3 days ago

$VANI This isn’t Johnson and Johnson, not $114 a share; but it can easily be acquired by such conglomerates, which would not be shocking. The potential for what it can do to the diabetes and fat loss market worldwide, and just medicine in general - could be astounding, I would love to see a double or triple digit figure for this ticker…

User Image PMR_ Posted - 3 days ago

$VANI Does anyone understand how they are able to use semaglutide for NPM-139? I looked through the 10-K but didn't see anything about licensing from Novo Nordisk, and I think the semiglutide patent doesn't expire until 2031. Excited about $VANI's potential and would love to get an implant twice a year to deliver all of my prescription meds! Perhaps compounding multiple drugs into their implant delivery system is on the horizon?

User Image Pathonix Posted - 3 days ago

$VANI - I could post lots of great things however, there really isn't a need. VANI is in my opinion going to make a move in due time.

User Image Aviator47 Posted - 3 days ago

$VANI @Pathonix I have followed you on here for a bit and I’m tracking what you are throwing down, happy to say more shares were bought today, looking forward to what the future brings for $VANI

User Image Readyplayer1111 Posted - 4 days ago

@Sliver Because it's a garbage chart and a garbage stock pumped by the pampers. Yet NO one talks about $VANI which is a legit company with legit upside potential.

User Image zeidbullish Posted - 4 days ago

$VANI why did this dropped from 7 dollars

User Image Pathonix Posted - 4 days ago

$VANI Those who have done the research know the value here https://ragingbiotechbuzz.blogspot.com/2024/02/clock-ticking-vivani-prepares-to.html

User Image Stocksprofessional Posted - 4 days ago

$VANI long and strong

User Image Pathonix Posted - 4 days ago

$VANI Don't forget the real money this will have when others see it's going to succeed.

User Image Aviator47 Posted - 1 week ago

$VANI this is going to be interesting.

User Image Readyplayer1111 Posted - 1 week ago

$VANI This has been consolidating for some time now. Hmmm

User Image Readyplayer1111 Posted - 1 week ago

$VANI Have a good feeling.

User Image Kkai14 Posted - 1 week ago

$VANI WHEN $20 ZZZZzzzzzzz

User Image Pathonix Posted - 1 week ago

$VANI https://ragingbiotechbuzz.blogspot.com/2024/02/clock-ticking-vivani-prepares-to.html

User Image Pathonix Posted - 1 week ago

$VANI Implant technology offers a more convenient & long-lasting treatment compared to weekly injections or daily oral administration required by drugs like Ozempic. Vivani's implant operates seamlessly without any moving parts, unlike the ITCA 650 device which faced FDA approval challenges due to erratic drug delivery caused by its osmotic pump mechanism. This difference is crucial. Vavani's results are better than the average 15-20% weight loss seen with Ozempic and similar drugs. Vivani's technology is attractive to major pharmaceutical companies. Vivani's shift towards combating obesity and the potential of its NPM-139 (semaglutide implant) with the potential for once-yearly dosing are seen as positive developments. Analysts believe that biotech companies that create these types of drugs with positive results will most likely be acquired, presenting an attractive investment opportunity.

User Image Pathonix Posted - 1 week ago

$VANI only had to hit .04 cents more today from the high of the day and it would have signaled a breakout

User Image Pathonix Posted - 1 week ago

$VANI Pellet implants for precise and steady obesity drug delivery is on the way let by VANI Big Pharma is ready to pounce the evidence is available. Something big is coming FACT

User Image Pathonix Posted - 1 week ago

$VANI $2.11 is a breakout signal if this area breaks on the day today

User Image WallStArb Posted - 1 week ago

@Digital_Waffle_Pirate GLP is imo a dying theme with scam cos like $VERU getting attention… as if $VANI or $VERU have any expertise even the most talentless big pharmas don’t have is laughable… good shorts to $0 as they are loaded with debt and will just dilute every uptick like $VINC

User Image ItsSamJam Posted - 1 week ago

$UCAR incase anybody getting bore here then can add $vani for next few days.. may get some thrill 🎵🎵🎵🎵

User Image KnowsNothing34 Posted - 1 week ago

$VANI when are their trial announcement dates? If someone is board watching and doesn't mind.

User Image ACInvestorBlog Posted - 1 week ago

$VANI back up

Analyst Ratings
ThinkEquity Buy Dec 5, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Williams Gregg Director Director Feb 05 Buy 1.01 1,995 2,015 724,340 02/06/24
Williams Gregg Director Director Jan 31 Buy 1.01 100 101 722,345 02/02/24
Williams Gregg Director Director Jan 23 Buy 1.01 834 842 722,245 01/25/24
Williams Gregg Director Director Jan 22 Buy 1.01 7,620 7,696 721,411 01/22/24
Williams Gregg Director Director Jan 18 Buy 1.01 1,076 1,087 713,791 01/19/24
Williams Gregg Director Director Jan 16 Buy 1.01 13,067 13,198 712,715 01/16/24
Williams Gregg Director Director Jan 08 Buy 1.08 6,731 7,269 699,648 01/09/24
Williams Gregg Director Director Jan 04 Buy 1.08 6,200 6,696 692,917 01/05/24
Williams Gregg Director Director Jan 02 Buy 1.01 7,111 7,182 686,717 01/03/24
Williams Gregg Director Director Dec 22 Buy 1.00 100 100 679,606 12/27/23
Williams Gregg Director Director Dec 19 Buy 0.87 153,872 133,869 679,506 12/21/23
Williams Gregg Director Director Dec 14 Buy 0.89 4,301 3,828 525,634 12/18/23
Makes Brigid CFO CFO Dec 15 Buy 0.88 5,000 4,400 15,000 12/18/23
Williams Gregg Director Director Dec 11 Buy 0.88 29,806 26,229 521,333 12/13/23
Williams Gregg Director Director Dec 06 Buy 0.96 993 953 491,527 12/08/23
Williams Gregg Director Director Nov 22 Buy 0.95 3,463 3,290 490,534 11/27/23
Dwyer Donald Chief Business Offic.. Chief Business Officer Nov 20 Buy 0.96 5,500 5,280 36,500 11/22/23
Williams Gregg Director Director Nov 16 Buy 0.95 3,266 3,103 487,071 11/20/23
Williams Gregg Director Director Oct 20 Buy 1 103,368 103,368 483,805 10/24/23
Williams Gregg Director Director Oct 12 Buy 1 12,419 12,419 380,437 10/16/23
Williams Gregg Director Director Oct 09 Buy 1.00 664 664 368,018 10/11/23
Williams Gregg Director Director Oct 06 Buy 1.02 87,887 89,645 367,354 10/10/23
Williams Gregg Director Director Oct 03 Buy 1 9,924 9,924 279,467 10/05/23
Williams Gregg Director Director Sep 28 Buy 1.02 36,210 36,934 269,543 10/02/23
Dwyer Donald Chief Business Offic.. Chief Business Officer Sep 27 Buy 1.01 1,000 1,010 31,000 09/27/23
Williams Gregg Director Director Sep 25 Buy 0.96 26,681 25,614 233,333 09/27/23
Williams Gregg Director Director Sep 20 Buy 0.93 21,426 19,926 206,652 09/22/23
Williams Gregg Director Director Sep 14 Buy 0.96 101,779 97,708 185,226 09/18/23
Williams Gregg Director Director Sep 08 Buy 0.95 13,997 13,297 83,447 09/12/23
Williams Gregg Director Director Sep 05 Buy 0.94 53,267 50,071 69,450 09/07/23
Dwyer Donald Chief Business Offic.. Chief Business Officer Aug 31 Buy 0.94 7,500 7,050 30,000 09/05/23
Makes Brigid CFO CFO Aug 31 Buy 0.92 6,000 5,520 10,000 09/05/23
Williams Gregg Director Director Aug 31 Buy 0.93 16,183 15,050 16,183 09/01/23
Makes Brigid CFO CFO Jun 27 Buy 1.23 4,000 4,920 4,000 06/29/23
Dwyer Donald Chief Business Offic.. Chief Business Officer Jun 22 Buy 1.24 5,000 6,200 15,000 06/26/23
Mendelsohn Aaron Director Director Jun 09 Buy 1.298 10,000 12,980 188,170 06/12/23
Williams Gregg Director Director Apr 27 Buy 1.04 2,040,494 2,122,114 13,677,308 05/01/23
Bolck Joachim Eberhard 10% Owner 10% Owner Jan 03 Buy 0.9 20,000 18,000 2,524,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Dec 27 Buy 1.02 30,000 30,600 2,514,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Dec 21 Buy 0.95 40,000 38,000 2,504,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Dec 19 Buy 0.93 29,000 26,970 2,484,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Nov 15 Buy 1.64 2,000 3,280 537,665 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Oct 21 Buy 1.8 26,400 47,520 2,470,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Oct 14 Buy 1.76 14,668 25,816 2,457,229 04/25/23
Bolck Joachim Eberhard 10% Owner 10% Owner Sep 12 Buy 3.15 15,568 49,039 2,450,895 04/25/23
Williams Gregg Director Director Jun 13 Buy 2 3,800 7,600 11,237,147 06/15/22
Williams Gregg Director Director Jun 03 Buy 2.4617 3,960 9,748 11,233,347 06/07/22
Williams Gregg Director Director May 31 Buy 2.31 312,493 721,859 11,173,949 06/02/22
Williams Gregg Director Director May 23 Buy 1.98 222,598 440,744 10,916,894 05/25/22
Williams Gregg Director Director May 18 Buy 1.79 803,487 1,438,242 10,694,296 05/20/22